Figure 6
Figure 6. In vivo growth inhibition of plasmacytoma by intramuscular injection of AdCMV.NK4. A total of 1 × 107 HGF-producing KMS11 (A) and KMS34 cells (B) were inoculated subcutaneously into lcr/scid mice and a plasmacytoma was established. When the tumors reached 100 mm3 (day 0), 5 × 108 infectious particles/mL AdCMV.NK4 or AdCMV.lacZ was injected into the femoral muscle on days 0 and 7. In Dex-sensitive KMS11 tumors, 0.8 μg/g Dex was also injected into the femoral muscle on days 0 and 7. The width and length of the plasmacytoma was measured every 3 days. Sizes on day 30 in each arm were compared and evaluated by the Student t test.

In vivo growth inhibition of plasmacytoma by intramuscular injection of AdCMV.NK4. A total of 1 × 107 HGF-producing KMS11 (A) and KMS34 cells (B) were inoculated subcutaneously into lcr/scid mice and a plasmacytoma was established. When the tumors reached 100 mm3 (day 0), 5 × 108 infectious particles/mL AdCMV.NK4 or AdCMV.lacZ was injected into the femoral muscle on days 0 and 7. In Dex-sensitive KMS11 tumors, 0.8 μg/g Dex was also injected into the femoral muscle on days 0 and 7. The width and length of the plasmacytoma was measured every 3 days. Sizes on day 30 in each arm were compared and evaluated by the Student t test.

Close Modal

or Create an Account

Close Modal
Close Modal